Symbio Pharmaceuticals Ltd. has entered into a sponsored research agreement with Tufts University to conduct joint research on the intravenous formulation of the antiviral drug brincidofovir.
Increased payload capacity for gene therapies, off-the-shelf genome-engineered allogeneic cell therapies, reduced cost of goods and faster bioprocesses, are promised by “big DNA” specialist Replay Holdings LLC. The newco arrived with a $55 million seed round and having assembled a portfolio of technologies for writing and delivering large pieces of DNA.
A team of researchers has created peptide-like molecules – "peptoids" – with antiviral properties that could circumvent the naturally occurring antimicrobial peptides' shortcomings.
Aicuris Anti-Infective Cures AG is beginning the pivotal phase III part of its trial of pritelivir for herpes simplex virus infection after an encouraging midstage readout.
A German-American team of researchers has developed a compound that could affect latent herpes simplex virus (HSV) infections, reducing the risk of recurrence even after an infection had fully established itself in its neuronal reservoir.
